{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urticaria&page=5", "query": { "condition": "Urticaria", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 224, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urticaria&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urticaria&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T10:59:29.718Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05392114", "title": "A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "Donidalorsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 154, "start_date": "2022-07-13", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 16, "location_summary": "Paradise Valley, Arizona • La Jolla, California • Santa Monica, California + 13 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05392114" }, { "nct_id": "NCT00628108", "title": "Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Allergic Rhinitis", "Chronic Urticaria" ], "interventions": [ { "name": "Levocetirizine 1.25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "11 Months", "sex": "ALL", "summary": "6 Months to 11 Months" }, "enrollment_count": 69, "start_date": "2008-03", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00628108" }, { "nct_id": "NCT04612790", "title": "A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bullous Pemphigoid" ], "interventions": [ { "name": "Benralizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 67, "start_date": "2021-03-31", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Centennial, Colorado + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Margate", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04612790" }, { "nct_id": "NCT06077773", "title": "Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Oral EP262", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Escient Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 113, "start_date": "2023-09-25", "completion_date": "2025-01-16", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06077773" }, { "nct_id": "NCT03661866", "title": "A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atopic Dermatitis", "Alopecia Areata", "Hidradenitis Suppurativa", "Vitiligo", "Psoriasis", "Chronic Spontaneous Urticaria" ], "interventions": [], "intervention_types": [], "sponsor": "Target PharmaSolutions, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15000, "start_date": "2018-12-21", "completion_date": "2050-12", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 54, "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03661866" }, { "nct_id": "NCT01292473", "title": "A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Idiopathic Urticaria" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Omalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 323, "start_date": "2011-03", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2013-10-11", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 36, "location_summary": "La Jolla, California • Los Angeles, California • Redwood City, California + 31 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01292473" }, { "nct_id": "NCT04180488", "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "6 Years to 80 Years" }, "enrollment_count": 397, "start_date": "2019-12-11", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 16, "location_summary": "Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180488" }, { "nct_id": "NCT05695248", "title": "A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "Navenibart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astria Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-02-21", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695248" }, { "nct_id": "NCT01386658", "title": "A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "icatibant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 32, "start_date": "2012-01-27", "completion_date": "2018-03-12", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 12, "location_summary": "Los Angeles, California • Tampa, Florida • Shreveport, Louisiana + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01386658" }, { "nct_id": "NCT04210843", "title": "Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Ligelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1033, "start_date": "2020-04-08", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-10-21T10:59:29.718Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210843" } ] }